Litcius/Paper detail

Discovery of Novel CCR5 Ligands as Anticolorectal Cancer Agents by Sequential Virtual Screening

Mariam A. El‐Zohairy, Darius P. Zlotos, Martin R. Berger, Hassan Adwan, Yasmine M. Mandour

2021ACS Omega18 citationsDOIOpen Access PDF

Abstract

drastically decreasing the CCR5 expression and cellular migration 48 h post treatment, indicating its ability to inhibit metastatic activity in SW620 cells. The discovered hits represent potential leads for the development of novel classes of anticolorectal cancer agents targeting CCR5.

Topics & Concepts

PharmacophoreVirtual screeningMaravirocChemokine receptor CCR5Chemokine receptorDocking (animal)CCR5 receptor antagonistCancer researchCell cycleIn vitroCancerComputational biologyLigand (biochemistry)ChemistryChemokineReceptorApoptosisBiologyHuman immunodeficiency virus (HIV)ImmunologyMedicineBiochemistryGeneticsNursingvaccines and immunoinformatics approachesChemokine receptors and signalingMonoclonal and Polyclonal Antibodies Research
Discovery of Novel CCR5 Ligands as Anticolorectal Cancer Agents by Sequential Virtual Screening | Litcius